Moderna 2022 Priorities and Capital Allocation
Spikevax'sⓇ market share has increased - and stayed consistent -
across key markets
Booster market in OECD countries continues to be an mRNA vaccine market
27%
+16%
45%
SpikevaxⓇ Booster/Third Dose Cumulative Market Share
+45%
+49%
57%
56%
54%
52%
+10%
+33%
43%
43%
44%
+23%
39%
37%
34%
32%
33%
10%
11%
+9%
+30%
44%
34%
35%
32%
4%
3%
2%
Oct Feb
'21 122
Apr
Oct
Feb
Apr
Oct
Feb Apr
Oct
Feb
Apr
Oct
122
'21
122
122
'21
122
122
'21
'22
'22
'21
122
Feb Apr
'22
Oct Feb
'21 122
Apr
Oct Feb Apr
122
'21
122
122
121
Oct Feb Apr
'22 122
(+)
H
Sources: All data shown is until 04/17, except Canada which is ending 04/10; all the historical data might be restated in the future).
Includes 4th dose data for Canada and South Korea
US: Booster authorized in ages 65+, high-risk individuals on Oct. 20; Booster authorized in ages 18+ on Nov. 19;
https://data.cdc.gov/Vaccinations/COVID-19-Vaccinations-in-the-United-States-Juris di/unsk-b7fc (based on 'additional dose' dat a field)
CA: Booster authorized in 18+ years old on Nov. 15, 2021: https://health-infobase.canada.ca/covid-19/vaccine-administration/
EU: Booster recommended in ages 18+ on Oct. 25; https://www.ecdc.europa.eu/en/publications-data/data-covid-19-vaccination-eu-eea
SK: Moderna vaccine granted EUA on Oct. 26, 2021; https://ncv.kdca.go.kr/vaccineStatus.es?mid=a11710000000
JP: Booster authorized on Nov 11, 2021; https://www.kantei.go.jp/
Slide 5
Methodology:
Oct 21 Cumulative Modema share of administered booster/3rd doses 10/3-10/31/21
Feb '22 Cumulative Moderna share of administered booster/3rd doses 10/3/21-2/13/22
Apr 122 Cumulative Moderna share of administered booster/3rd doses 10/3/21-4/17/22
Share is calculated for Third Dose (vast majority is booster; may include 3rd for immuno-compromised);
Canada and South Korea also include 4th dose since data is explicitly reported
Share is only calculated for doses where manufacturer has been identified in the public data source
modernaView entire presentation